Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery

John P. Maurice, Jonathan A. Hata, Ashish S. Shah, David C. White, Patricia H. McDonald, Paul C. Dolber, Katrina H. Wilson, Robert J. Lefkowitz, Donald D. Glower, Walter J. Koch

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Exogenous gene delivery to alter the function of the heart is a potential novel therapeutic strategy for treatment of cardiovascular diseases such as heart failure (HF). Before gene therapy approaches to alter cardiac function can be realized, efficient and reproducible in vivo gene techniques must be established to efficiently transfer transgenes globally to the myocardium. We have been testing the hypothesis that genetic manipulation of the myocardial β-adrenergic receptor (β-AR) system, which is impaired in HF, can enhance cardiac function. We have delivered adenoviral transgenes, including the human β2-AR (Adeno-β2AR), to the myocardium of rabbits using an intracoronary approach. Catheter-mediated Adeno-β2AR delivery produced diffuse multichamber myocardial expression, peaking 1 week after gene transfer. A total of 5 x 1011 viral particles of Adeno-β2AR reproducibly produced 5- to 10-fold β-AR overexpression in the heart, which, at 7 and 21 days after delivery, resulted in increased in vivo hemodynamic function compared with control rabbits that received an empty adenovirus. Several physiological parameters, including dP/dt(max) as a measure of contractility, were significantly enhanced basally and showed increased responsiveness to the β-agonist isoproterenol. Our results demonstrate that global myocardial in vivo gene delivery is possible and that genetic manipulation of β-AR density can result in enhanced cardiac performance. Thus, replacement of lost receptors seen in HF may represent novel inotropic therapy.

Original languageEnglish (US)
Pages (from-to)21-29
Number of pages9
JournalJournal of Clinical Investigation
Volume104
Issue number1
StatePublished - Jul 1999
Externally publishedYes

Fingerprint

Adrenergic Receptors
Heart Failure
Transgenes
Genes
Myocardium
Rabbits
Genetic Testing
Isoproterenol
Adenoviridae
Genetic Therapy
Virion
Cardiovascular Diseases
Therapeutics
Catheters
Hemodynamics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Maurice, J. P., Hata, J. A., Shah, A. S., White, D. C., McDonald, P. H., Dolber, P. C., ... Koch, W. J. (1999). Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery. Journal of Clinical Investigation, 104(1), 21-29.

Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery. / Maurice, John P.; Hata, Jonathan A.; Shah, Ashish S.; White, David C.; McDonald, Patricia H.; Dolber, Paul C.; Wilson, Katrina H.; Lefkowitz, Robert J.; Glower, Donald D.; Koch, Walter J.

In: Journal of Clinical Investigation, Vol. 104, No. 1, 07.1999, p. 21-29.

Research output: Contribution to journalArticle

Maurice, JP, Hata, JA, Shah, AS, White, DC, McDonald, PH, Dolber, PC, Wilson, KH, Lefkowitz, RJ, Glower, DD & Koch, WJ 1999, 'Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery', Journal of Clinical Investigation, vol. 104, no. 1, pp. 21-29.
Maurice, John P. ; Hata, Jonathan A. ; Shah, Ashish S. ; White, David C. ; McDonald, Patricia H. ; Dolber, Paul C. ; Wilson, Katrina H. ; Lefkowitz, Robert J. ; Glower, Donald D. ; Koch, Walter J. / Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery. In: Journal of Clinical Investigation. 1999 ; Vol. 104, No. 1. pp. 21-29.
@article{5a47c18dfd104ac5a4ee1867ff4e4b4e,
title = "Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery",
abstract = "Exogenous gene delivery to alter the function of the heart is a potential novel therapeutic strategy for treatment of cardiovascular diseases such as heart failure (HF). Before gene therapy approaches to alter cardiac function can be realized, efficient and reproducible in vivo gene techniques must be established to efficiently transfer transgenes globally to the myocardium. We have been testing the hypothesis that genetic manipulation of the myocardial β-adrenergic receptor (β-AR) system, which is impaired in HF, can enhance cardiac function. We have delivered adenoviral transgenes, including the human β2-AR (Adeno-β2AR), to the myocardium of rabbits using an intracoronary approach. Catheter-mediated Adeno-β2AR delivery produced diffuse multichamber myocardial expression, peaking 1 week after gene transfer. A total of 5 x 1011 viral particles of Adeno-β2AR reproducibly produced 5- to 10-fold β-AR overexpression in the heart, which, at 7 and 21 days after delivery, resulted in increased in vivo hemodynamic function compared with control rabbits that received an empty adenovirus. Several physiological parameters, including dP/dt(max) as a measure of contractility, were significantly enhanced basally and showed increased responsiveness to the β-agonist isoproterenol. Our results demonstrate that global myocardial in vivo gene delivery is possible and that genetic manipulation of β-AR density can result in enhanced cardiac performance. Thus, replacement of lost receptors seen in HF may represent novel inotropic therapy.",
author = "Maurice, {John P.} and Hata, {Jonathan A.} and Shah, {Ashish S.} and White, {David C.} and McDonald, {Patricia H.} and Dolber, {Paul C.} and Wilson, {Katrina H.} and Lefkowitz, {Robert J.} and Glower, {Donald D.} and Koch, {Walter J.}",
year = "1999",
month = "7",
language = "English (US)",
volume = "104",
pages = "21--29",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery

AU - Maurice, John P.

AU - Hata, Jonathan A.

AU - Shah, Ashish S.

AU - White, David C.

AU - McDonald, Patricia H.

AU - Dolber, Paul C.

AU - Wilson, Katrina H.

AU - Lefkowitz, Robert J.

AU - Glower, Donald D.

AU - Koch, Walter J.

PY - 1999/7

Y1 - 1999/7

N2 - Exogenous gene delivery to alter the function of the heart is a potential novel therapeutic strategy for treatment of cardiovascular diseases such as heart failure (HF). Before gene therapy approaches to alter cardiac function can be realized, efficient and reproducible in vivo gene techniques must be established to efficiently transfer transgenes globally to the myocardium. We have been testing the hypothesis that genetic manipulation of the myocardial β-adrenergic receptor (β-AR) system, which is impaired in HF, can enhance cardiac function. We have delivered adenoviral transgenes, including the human β2-AR (Adeno-β2AR), to the myocardium of rabbits using an intracoronary approach. Catheter-mediated Adeno-β2AR delivery produced diffuse multichamber myocardial expression, peaking 1 week after gene transfer. A total of 5 x 1011 viral particles of Adeno-β2AR reproducibly produced 5- to 10-fold β-AR overexpression in the heart, which, at 7 and 21 days after delivery, resulted in increased in vivo hemodynamic function compared with control rabbits that received an empty adenovirus. Several physiological parameters, including dP/dt(max) as a measure of contractility, were significantly enhanced basally and showed increased responsiveness to the β-agonist isoproterenol. Our results demonstrate that global myocardial in vivo gene delivery is possible and that genetic manipulation of β-AR density can result in enhanced cardiac performance. Thus, replacement of lost receptors seen in HF may represent novel inotropic therapy.

AB - Exogenous gene delivery to alter the function of the heart is a potential novel therapeutic strategy for treatment of cardiovascular diseases such as heart failure (HF). Before gene therapy approaches to alter cardiac function can be realized, efficient and reproducible in vivo gene techniques must be established to efficiently transfer transgenes globally to the myocardium. We have been testing the hypothesis that genetic manipulation of the myocardial β-adrenergic receptor (β-AR) system, which is impaired in HF, can enhance cardiac function. We have delivered adenoviral transgenes, including the human β2-AR (Adeno-β2AR), to the myocardium of rabbits using an intracoronary approach. Catheter-mediated Adeno-β2AR delivery produced diffuse multichamber myocardial expression, peaking 1 week after gene transfer. A total of 5 x 1011 viral particles of Adeno-β2AR reproducibly produced 5- to 10-fold β-AR overexpression in the heart, which, at 7 and 21 days after delivery, resulted in increased in vivo hemodynamic function compared with control rabbits that received an empty adenovirus. Several physiological parameters, including dP/dt(max) as a measure of contractility, were significantly enhanced basally and showed increased responsiveness to the β-agonist isoproterenol. Our results demonstrate that global myocardial in vivo gene delivery is possible and that genetic manipulation of β-AR density can result in enhanced cardiac performance. Thus, replacement of lost receptors seen in HF may represent novel inotropic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032745831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032745831&partnerID=8YFLogxK

M3 - Article

C2 - 10393695

AN - SCOPUS:0032745831

VL - 104

SP - 21

EP - 29

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -